SCHEDULE: Laxminarayan Bhat Amends Reviva Pharmaceuticals Holdings Stake, Reports 5.2% Beneficial Ownership

Laxminarayan Bhat has filed Amendment No. 5 to his Schedule 13D, disclosing a beneficial ownership of 5.2% of Reviva Pharmaceuticals Holdings, Inc.'s common stock, totaling 3,612,384 shares.

Summary

• Laxminarayan Bhat, the Reporting Person, filed Amendment No. 5 to the Schedule 13D relating to the common stock of Reviva Pharmaceuticals Holdings, Inc.
• As of the filing date of July 1, 2025, the Reporting Person beneficially owns an aggregate of 3,612,384 shares of Common Stock.
• This ownership represents approximately 5.2% of the 68,003,613 outstanding shares of Common Stock as reported by the Issuer as of July 1, 2025.
• The Reporting Person holds sole voting and dispositive power over 3,301,282 shares, which includes 2,478,856 directly held shares and 822,426 shares issuable upon the exercise of options exercisable within 60 days.
• Shared voting and dispositive power is held over 311,102 shares, consisting of 5,388 shares held by the Reporting Person's spouse and 305,714 shares issuable upon the exercise of options held by the spouse that are exercisable within 60 days.
• The reported beneficial ownership excludes 298,025 unvested options held by the Reporting Person and 103,629 unvested options held by the Reporting Person's spouse, as these are not exercisable within 60 days of the filing date.
• No transactions in the Common Stock or convertible securities were effected by the Reporting Person during the 60 days prior to the filing date.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects.

Positives

• The document is a factual ownership disclosure and does not contain explicit positive statements regarding company performance or outlook.

Negatives

• The document is a factual ownership disclosure and does not contain explicit negative statements regarding company performance or outlook.

Risks

• The document is a beneficial ownership filing and does not detail specific company risks or future challenges.

Future Outlook

The document is a beneficial ownership filing and does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of beneficial ownership and does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• This document is a standard Schedule 13D amendment, which is a regulatory filing for disclosing significant ownership stakes. It does not contain information for direct comparison to industry-specific operational or financial benchmarks of comparable companies or projects.

Related Party Transactions

• The beneficial ownership calculation includes 5,388 shares of Common Stock held by the Reporting Person's spouse and 305,714 shares of Common Stock issuable upon the exercise of options held by the Reporting Person's spouse that are exercisable within 60 days.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership stake of a significant individual, which can influence perceptions of insider alignment and control.

Key Dates

Keywords

Reviva Pharmaceuticals Holdings Inc., Laxminarayan Bhat, Schedule 13D, Beneficial Ownership, Common Stock, SEC Filing, Ownership Stake, Pharmaceuticals, Biotechnology